Latest: GLG Healthcare Newsletter 2023

Our lab-based professional network increased by 68% this past year. 

GLG is dedicated to becoming your primary resource for lab-based market research. Our efforts remain the same this year, with a focus on ensuring the best quality, volume, diversity, and accessibility. The continuous feedback from our clients’ engagements with lab decision makers and influencers allows our team to ensure we meet market needs and expectations. 

Our recent recruitment efforts led to: 

• A 27% increase in our nonclinical population, including key experts across biotech, biopharma, and pharma; CROs; CDMOs; and translational research labs.
• Our clinical population increasing by 100%, including a wide range of stakeholders from academic hospitals, standalone hospitals, health systems, provider reference labs, and independent reference labs.
• The consistent growth of lab-based professionals to our network from C-suite and management to end users.

We understand the nuances of this niche population. Our teams work directly with lab professionals – as we do across all industries – to provide critical insights to our clients.

What can you expect to see in 2023? 

In the coming months, we are committed to reengaging and adding more than 500 Network Members across an array of clinical and nonclinical backgrounds. Our efforts will capture the most frequently identified points of qualification, including decision-making power, total throughput, tests and techniques used, and more.

If you have a specific need or would like to connect to learn more about this population today, get in touch with our team.

FEATURED INSIGHTS

At-Home Healthcare After COVID-19 | Read More

GLG Social Impact Fellow Manmeet Kaur provides insight into the home care industry, including how companies are adapting to meet the increased demand and the challenges companies are still working to address. 

Inflation Reduction Act — Drug Pricing Provisions | Watch Now

What challenges and opportunities can individuals, pharmaceutical companies, and the drug supply chain expect? Dr. Joshua Cohen discusses the IRA’s drug pricing provisions and more.